Jul. 30 at 2:51 AM
$HROW From BLCO: "MIEBO’s revenue grew 44% to
$91 million in the quarter, while XIIDRA grew 6% to
$87 million. Individually, those are strong numbers. Together, they tell a bigger story. MIEBO and XIIDRA delivering 27% combined revenue growth in the first half of this year versus the first half of 2025. That’s why we’re increasingly confident in what comes next. Based on where MIEBO is trending, we expect it to soon become the branded industry leader in the treatment of dry eye disease, a category with real unmet patient need and a treatment landscape that’s been waiting for a differentiated option. That’s the position MIEBO was built to fill. Paired with XIIDRA, a proven established therapy with its own loyal prescriber base, we have a dry eye portfolio that competes on both ends of the treatment paradigm."
